
Are your MRI contrast agents cost-effective?







Single-Photon Emission CT for the Diagnosis of Malignant Meningiomas

Technetium Tc99m-Tetrofosmin Brain

G.A. Alexiou, S. Voulgaris, S. Tsiouris, A.D. Fotopoulos, A.P. Kyritsis and K.S. Polyzoidis

This information is current as of April 20, 2024.

AJNR Am J Neuroradiol 2009, 30 (2) e21 doi: https://doi.org/10.3174/ajnr.A1286 http://www.ajnr.org/content/30/2/e21

Technetium Tc99m-Tetrofosmin Brain Single-Photon Emission CT for the Diagnosis of Malignant Meningiomas

We read with great interest a recent article by Nagar et al¹ in the American Journal of Neuroradiology investigating the usefulness of diffusion-weighted MR imaging in differentiating atypical/malignant meningiomas from benign meningiomas and detecting histologic dedifferentiation to higher tumor grade. The authors studied 48 cases of meningiomas and found that the mean apparent diffusion coefficient and normalized apparent diffusion coefficient ratios of atypical/malignant meningiomas were significantly lower compared with benign meningiomas. The mean apparent diffusion coefficient and normalized apparent diffusion coefficient cutoff threshold values representatively discriminating the 2 clinical entities was $0.80 \times 10(-3)$ mm²/s and 0.99, respectively, as indicated by the receiver operating characteristic curve analysis. Finally, diffusion-weighted MR imaging gave promise in the detection of meningioma histologic dedifferentiation to higher tumor grade. ¹

Our ongoing research deals with the usefulness of functional brain tumor imaging by single-photon emission CT (SPECT). We currently investigate the imaging properties of technetium-Tc99m-tetrofosmin (99mTc-TF), a lipophilic diphosphine routinely used for myocardial perfusion imaging that also displays tumor-seeking properties. We evaluated prospectively whether 99mTc-TF uptake correlates with the cellular proliferative activity of the meningioma (as assessed by Ki-67 index and flow cytometry) and grade. We found that 99mTc-TF SPECT can reliably distinguish typical meningiomas from malignant meningiomas. A significant correlation of radiotracer uptake with both Ki-67 expression and the percentage of the cell fraction on S phase and the level of aneuploidy of meningiomas^{2,3} was also detected. Furthermore, there was a significant correlation between the intensity of tracer uptake and tumor recurrence 1 year postoperatively.²

Meningiomas constitute approximately 20% of all intracranial tumors, and though they usually have a relatively benign clinical course and only a 15% recurrence rate, atypical and malignant meningiomas

are associated with high recurrence rates and poor outcome.⁴ Apart from tumor grade, the Ki-67 index and status of DNA ploidy and S phase (as determined by flow cytometry) have been directly correlated with the biologic behavior of the meningioma.^{4,5} Because ^{99m}Tc-TF brain SPECT has a favorable cost and is widely available, we propose this imaging technique as an alternative method for the differentiation of typical from malignant meningiomas that, in addition, provides a noninvasive estimation of the proliferative potential of meningiomas.

References

- Nagar VA, Ye JR, Ng WH, et al. Diffusion-weighted MR imaging: diagnosing atypical or malignant meningiomas and detecting tumor dedifferentiation. AJNR Am J Neuroradiol 2008;29:1147–52
- Fotopoulos AD, Alexiou GA, Goussia A, et al. (99m)Tc-Tetrofosmin brain SPECT in the assessment of meningiomas-correlation with histological grade and proliferation index. J Neurooncol 2008;89:225–30
- Alexiou GA, Vartholomatos G, Tsiouris S, et al. Evaluation of meningioma aggressiveness with ^{99m}Tc-Tetrofosmin SPECT. Clin Neurol Neurosurg 2008;110:645–48
- Kasuya H, Kubo O, Tanaka M, et al. Clinical and radiological features related to the growth potential of meningioma. Neurosurg Rev 2006;29:293–96
- Zellner A, Meixensberger J, Roggendorf W, et al. DNA ploidy and cell-cycle analysis in intracranial meningiomas and hemangiopericytomas: a study with high-resolution DNA flow cytometry. Int J Cancer 1998;79:116–20

G.A. Alexiou
S. Voulgaris
Department of Neurosurgery
S. Tsiouris
A.D. Fotopoulos
Department of Nuclear Medicine
A.P. Kyritsis
Department of Neurology and Neurosurgical Institute
K.S. Polyzoidis
Department of Neurosurgery and Neurosurgical Institute
University Hospital of Ioannina
Ioannina, Greece

DOI 10.3174/ajnr.A1286